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A CORRELATIVE STUDY OF THE CHOLINESTERASE ACTIVITY OF
BRAIN AND BLOOD
CHAPTER I 
INTRODUCTION
The physiological role of acetylcholine as a chemical 
transmitter of the nerve impulse in the peripheral nervous 
system has been known for many years. However, it has only 
been a few years that acetylcholine has been generally 
considered to serve the same function in the central nervous 
system. Since many vital functions of the body are regulated 
by the nervous system, and since cholinesterase has an 
important role in the metabolism of acetylcholine, elevated 
or lowered cholinesterase activity may have a profound 
influence in producing an alteration in these functions.
Enzymology has contributed a great deal to our present
understanding of intra- and extracellular processes. This
was made possible primarily by correlating enzymatic activity
with the function of its substrate. The effect of drugs on
enzyme systems has also emerged as a worthwhile field of
pharmacological investigation. Some examples are those
systems including the enzymes catalase, hexokinase, carbonic
1
2anhydrase, succinic dehydrogenase and cholinesterase.
The inhibition of enzyme systems is known to occur and 
decreased cholinesterase activity has been associated with 
some toxicological and pathological processes. The toxic 
symptoms resulting from absorption of the organic phosphorus 
insecticides has been related to cholinesterase inhibition 
in the central as well as in the peripheral nervous system. 
Most of these toxic symptoms may be explained on the basis 
of an accumulation of acetylcholine resulting from a decrease 
in cholinesterase activity. Decreased cholinesterase activi­
ty has also been indicted in disorders of the nervous system 
such as epilepsy and catatonic stupor. Increased cholin­
esterase activity has been reported in chronic psychotic 
patients and in mentally ill patients showing autonomic 
overactivity.
Since biopsies of brain cannot ordinarily be taken it 
would be desirable to know if a correlation exists between 
the cholinesterase activity of brain, blood, and cerebro­
spinal fluid. Koelle and Gilman (25), Freedman, Willis and 
Himwich (20), Hagan and Frawley (21), and Frawley et al.(IS) 
have conducted investigations to determine if a correlation 
exists between brain and blood cholinesterase activity and 
symptoms of toxicity following di-isopropyl fluorophosphate 
(DFP). Hagan and Frawley concluded that there was no 
correlation. The other three groups found no correlation
3between serum and brain cholinesterase activity and sympto- 
mology. Freedman et al. (20) believed there was a slight 
correlation between the cholinesterase activity of brain and 
erythrocytes and symptomology following acute toxicity. 
Frawley et al. (lô) believed that following a suspected 
acute exposure to a cholinesterase inhibitor, measurements 
of erythrocyte cholinesterase activity would be of little 
help in determining the degree of exposure and severity of 
symptoms. Further studies, particularly those of a 
correlative nature, are needed. Therefore, based on the 
above information, it was decided to study whether or not 
there was a correlation between the cholinesterase activity 
of parts of the brain, the cerebrospinal fluid, the 
erythrocytes, and blood plasma. This study was conducted 
in normal animals; animals treated with electroshock; and 
with drugs, particularly an irreversible cholinesterase 
inhibitor, di-isopropyl fluorophosphate (DFP).
CHAPTER II 
HISTORY
Elliott (15), in 1905, introduced the revolutionary 
idea of the chemical transmission of the nerve impulse.
He suggested that adrenaline might be the chemical mediator 
of the nerve impulse from sympathetic nerve endings to their 
effector cells. Subsequently, Loewi (29), in 1921, published 
experimental data showing the release of a substance which
he called "Vagusstoff ” into the perfusion fluid in a frog
».
heart when the vagus nerve was stimulated. When the perfusate 
from this heart was perfused into the heart of another frog, 
responses occurred which were similar to vagal stimulation. 
Hunt and Taveau (24) had previously demonstrated the 
pharmacological action of acetylcholine. Loewi and Navatril 
(30) extended the work of Loewi (27) and it led them to assume 
that "VagusStoff" is acetylcholine.
These early ideas and investigations comprise the 
actual beginning and basis of the concept of neurohumoral 
transmission of the nerve impulse. The hypothesis was that 
a chemical substance was liberated from nerve endings which 
served as a mediator for the initiation of the nerve impulse.
5Dale and Dudley (11) isolated acetylcholine from the spleen 
and showed it to be a natural constituent of the animal 
body. Dale and Feldberg (12) showed that acetylcholine was 
liberated into the blood stream following stimulation of the 
gastric vagus of the eserinized dog.
It is now known that the liberation of acetylcholine is 
not confined to vagal nerve endings but is also concerned 
with nerve impulse transmission at all ganglionic synapses. 
Acetylcholine is also the mediator for nerve impulses to 
skeletal muscles, sweat glands, chromaffin cells of the 
adrenal medulla, piloerector muscles, and at some central 
nervous system synapses.
The possibility of a chemical mediator at the central 
synapse was considered by Dale (9) as early as 1934. In 
his Harvey Lectures (8) in 1936, he discussed the fact that 
Eccles considered the sympathetic ganglion to be an accessible 
model of a synapse in the gray matter of the central nervous 
system. He later remarked that Sherrington had told him in 
those early years that he considered the myoneural junction 
to afford a model of the process occurring at the central 
synapse (10). Feldberg (16), in his review in 1945, gave 
a rather complete picture of the mode of action of acetyl­
choline in the central nervous system. At that time he 
stated, "The present position of the theory of acetylcholine 
as central transmitter is all but settled". Almost ten years
6later (17), when participating in the Symposium on Neuro- 
humoral Transmission, he considered the central synaptic and 
peripheral synaptic transmission processes to be fundamentally 
identical.
When it was demonstrated that acetylcholine played an 
essential physiological role in the nervous system, it is 
not surprising that many investigators soon turned their 
thoughts to a study of it s metabolism. In 1914, Dale (7) 
suggested the existence of an enzyme in blood which terminated 
the pharmacological response to injected acetylcholine. He 
believed this to be broght about by hydrolysis of the 
compound. It was in 1930 that Matthes (32) showed the enzy­
matic nature of this hydrolysis. In the same year, Plattner 
and Hinter (47) found the enzyme to be present in nearly 
all animal tissues. Using horse serum, Stedman et al. (60) 
found that butyrylcholine was hydrolyzed at a higher rate 
than acetylcholine, and that following partial purification, 
non-choline esters were not hydrolyzed. They believed the 
enzyme to be specific for choline esters and called it 
cholinesterase. Subsequent investigations did not support 
the contention that this enzyme was specific for choline 
esters. In fact, Vahlquist (64) showed that human serum 
esterase was not specific for choline esters, although they 
were hydrolyzed at a higher rate than non-choline esters.
About this time, Stedman and Stedman (59) pointed out that 
blood cholinesterase of various species did not seem to be
the same. They behaved quite differently with respect to 
rates of hydrolysis of different substrates. Then in 1940, 
Allés and Hawes (1) accomplished the first major step toward 
differentiating blood cholinesterase into its two components, 
serum and erythrocyte cholinesterase. They showed that 
erythrocyte cholinesterase is inhibited by an excess of 
substrate. This was in sharp contrast to serum cholinesterase 
which has no optimum substrate concentration. Further, they 
showed that only erythrocyte cholinesterase hydrolyzed 
acetyl-beta-methylcholine. Mendel and Rudney (34) extended 
this work and again utilizing substrate specificity as a 
means of differentiating the two enzymes, named the erythro­
cyte and serum enzymes, true- and pseudo-cholinesterase 
respectively. They also showed that the cholinesterase of 
conducting tissue is predominately of the true-cholinesterase 
type. Nachmansohn and Rothenberg (40,41) used three esters 
of choline differing only in the length of the acyl chain.
They found that the rate of hydrolysis of these esters by 
the enzyme of conducting tissue and erythrocytes increased 
as the acyl chain was decreased from butyryl to acetylcholine. 
The reverse was true for the serum esterase, i.je., the rate 
of hydrolysis being greatest for butyrylcholine. They 
suggested the name acetylcholinesterase for the esterase of 
erythrocytes and conducting tissue and cholinesterase for 
the serum esterase. Augustinsson (2,3) showed that at high
8acetylcholine concentrations, where the erythrocyte and 
nervous tissue cholinesterase activity was inhibited, 
triacetin was hydrolyzed, in some cases at a higher rate 
than acetylcholine.
It can be seen from the standpoint of chemical 
specificity that there is no sharp distinction between the 
true or specific and the pseudo or nonspecific types.
Neither is there a clear cut distribution of these two 
enzymes as might be expected at first glance. Ord and 
Thompson (45) have determined the distribution of these 
two types in various tissues using differential substrate 
specificity methods.
Sihce acetylcholine is concerned with vital functions 
of the nervous system, inhibitors of cholinesterase are of 
great concern. The physiological function of this enzyme- 
substrate system has been better ascertained through the 
use of these agents. One of the most familiar inhibitors 
is the alkaloid physostigmine, which forms a reversible 
complex with the enzyme. During World War II a second group 
of powerful cholinesterase inhibitors were synthesized which 
produced an irreversible inhibitor-enzyme complex (31,33). 
They were obtained from dialkylphosphoric acid esters. Since 
they are potential warfare agents, many investigations have 
been conducted to study their mode of action.
Koelle and Gilman (27) pointed out that although many
9drugs inhibit cholinesterase, this may be of minor importance 
in their pharmacological activity. Furthermore, specific 
inhibitors may also act directly upon the effector cells. 
However, most studies substantiate the fact that the major 
pharmacological effects of DFP are those resulting from 
cholinesterase inhibition. The results of Mazur and 
Bodansky (33); Koelle and Gilman (25); and Freedman, Willis 
and Himwich (20) indicated that the symptomology following 
DFP is closely related to a low brain cholinesterase activity. 
Koelle and Gilman (25) studied the regeneration rates of 
blood and brain cholinesterase activity following DFP.
They believed it was futile to attempt to relate symptomology 
to serum cholinesterase inhibition. Frawley et al. (IB) 
have presented the best evidence to date that some of the 
symptoms of toxicity resulting from DFP poisoning may be due 
to factors aside from cholinesterase inhibition.
Much of the work related to correlation between brain 
and blood cholinesterase activity following DFP has been 
done using rats. Groups of about six animals were used to 
determine the mean enzymatic activity. To this writer»s 
knowledge, no attempt has heretofore been made to establish 
a correlation between brain and blood cholinesterase activity 
in individual animals, particularly the dog.
In 1937, McGeorge (35) examined a group of hospitalized, 
depressive patients and could find no relationship between
10
the mental state of the patient and serum cholinesterase 
activity. In the same year. Tod and Jones (62) determined 
serum cholinesterase activity in patients who exhibited 
anxiety and depressive states. They found elevated serum 
cholinesterase activity in cases showing autonomic over­
activity. In the more acute cases, enzymatic activity was 
even higher. In another publication. Tod and Jones (63) 
found a significant difference between patients exhibiting 
anxiety states, catatonic stupor and epilepsy. Those with 
anxiety showed higher than normal serum cholinesterase 
activity while those with catatonic stupor and epilepsy 
showed lower than normal activity. Platania and Pappalardo 
(46) made a study of 100 mentally ill patients. Those 
showing schizophrenia with intense psychomotor activity 
seemed to have higher values of serum cholinesterase than 
the quiet ones. In the epileptic group, the value increased 
with the number of convulsions. They believed the nervous 
system regulated the amount of cholinesterase in blood 
serum. Early et al. (I4) found an elevated serum cholin­
esterase activity in over 50 per cent of their chronic 
psychotic patients. On the other hand, in some patients 
they reported no serum cholinesterase activity at all. They 
believed this to be due to lack of production of cholines­
terase. Ravin and Altschule (51) reported that the mean 
values of serum cholinesterase activity for a group of
11
mental patients were slightly higher than the mean of a 
control group. Following electroshock no significant 
change occurred although some patients improved while others 
did not. They reported a transient rise in serum cholin­
esterase activity following electroshock but believed this 
was probable due to hemoconeentrâtion which has been shown 
to occur. DeCaro and Altea (13) could find no significant 
change in cholinesterase activity in the blood of 53 patients 
and in the cerebral tissue and blood of rabbits following 
electroshock. Lagnara and Preziosa (2Ô) reported that 
following electroshock in 30 patients and after convulsions 
in 10 epileptics, serum cholinesterase activity was greatly 
increased associated with an increase in acetylcholine.
Takagi (61) reported that electroshock had no effect on 
cholinesterase. Rowntree et al. (54) found the erythrocyte 
cholinesterase activity to be in the normal range in 
schizophrenia and in manic depressive psychosis. However, 
they found that schizophrenics had more tolerance to DFP.
This they called autonomic hyporeactivity. Further 
depression of the manic depressive state was produced by 
DFP. The administration of DFP to the schizophrenic 
produced activation of the psychosis. Blood cholinesterase 
activities were the same in each group despite the different 
clinical effects produced by DFP. They also found those 
in the manic depressive state exhibited a rise in blood
12
pressure when given DFP. In 1952, Sherwood injected 
purified human erythrocyte cholinesterase into the lateral 
ventricles of a patient in deep catatonic stupor (55)«. 
Marked improvement resulted but following cessation of 
therapy the patient returned to the former catatonic 
state. Later, in another publication, Sherwood et al. (56) 
also demonstrated that anticholinesterases aggravated the 
signs and symptoms of schizophrenia. An interesting 
experiment was carried out by this group whereby they 
produced a syndrome in cats which they believed to be in­
distinguishable from that of human catatonia. The cats 
were made catatonic by producing lesions in the brain with 
a stereotaxic instrument. When cholinesterase was injected 
intraventricularly, recovery occurred within 2 days. When 
acetylcholine was injected via the same route, symptoms were 
again aggravated. Randall (49) administered large daily 
doses of insulin to schizophrenics and found an elevated 
serum cholinesterase activity in the 4th week of treatment. 
Randall and Jellinek (50) found an elevated serum cholin­
esterase activity in acute schizophrenics one week following 
insulin shock whether or not improvement occurred.
CHAPTER III 
METHODS 
Animals
Mongrel dogs ranging in weight from 9 to 17 Kg. were 
used. The animals were killed with air emboli. The air, 
which was injected into the cephalic vein through a hypodermic 
needle, was supplied by a small pump. Rubber tubing was 
used to connect the hypodermic needle to the pump. A T-tube 
was inserted in the tubing between the pump and the needle 
to provide a by-pass for the air to escape until the needle 
was inserted. When the needle was in the vein, the air 
was forced to enter by closing the side arm of the T,
Following cessation of respiration, the animals were bled 
by severing the juglar vein.
Tissues
(1) Brain. The brain was exposed in the following 
manner; An incision was made through the skin just below 
a point midway between the eyes which was extended just 
posterior to the occipital protuberance. The temporal 
muscles were cut away and an opening was made through the 
skull by means of a trephine. Bone forceps were used to
13
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remove the calavarium and expose the brain. The dura was 
reflected, the midbrain sectioned transversely, and the 
supratentorial portion of the brain removed. The brain 
specimen was then sectioned in half by cutting through the 
corpus callosum, third ventricle and hypothalamus in the 
midsagittal plane. The caudate nucleus is made accessible 
by removing the septum pellucidum. The right and left 
caudate nuclei were removed. When cerebral cortex was used, 
the arachnoid-pia layer was removed from the sulci and 
gyri approximating Brodmann Areas 4 and 6. The gray matter 
was freed as carefully as possible from the white matter. 
The tissue to be analyzed was weighed and ground in a 
ground-glass homogenizer. In experiments using metrazol, 
insulin, and atropine, a 1:0 homogenate of caudate nucleus 
in distilled water was made and centrfuged at about BOO G. 
for 15 minutes. The supernatant liquid was used to make a 
1:10 dilution. One ml. of this dilution was used to deter­
mine the cholinesterase activity. Later it was found that 
the greater part of brain cholinesterase activity remains 
with the precipitate. Therefore, in all subsequent experi­
ments, the whole homogenate was used. A 1:25 dilution was 
made using 1 ml. of the 1:8 homogenate. One ml. of this 
dilution was then used to determine the cholinesterase 
activity. In those experiments using cerebral cortex, a 1;8
homogenate in distilled water was made and 1 ml. of this 
dilution was used to determine the enzyme activity.
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(2) Blood, Heparin was used to prevent clotting and 
the blood was centrifuged at about 800 G. for 15 minutes.
The plasma was withdrawn and the erythrocytes were washed 
with 0,9^ NaCl solution and again centrifuged for 15 minutes* 
Following a second washing with 0*9% NaCl solution, the 
erythrocytes were centrifuged for 20 minutes and then 
suspended in 0,9^ NaCl solution as described by Michel (38),
(a) Plasma* The plasma was diluted with distilled 
water so that each ml. of solution contained 0,007 ml. of 
plasma. The buffer capacity of one ml. of this solution 
when mixed with one ml, of buffer (Buffer II under 
Determination of Cholinesterase Activity) averaged 7 per cent 
of the total as determined by titration between pH 8 and 7*
(b) Erythrocytes, One ml. of washed and 
suspended erythrocytes was hemolyzed in 4=8 ml, of 0,01 
per cent saponin solution. The buffer capacity of one ml, 
of the erythrocyte hemolysate when mixed vdth one ml, of 
Buffer I averaged 12 per cent of the total as determined 
by titration between pH 8 and 7»
(3) Cerebrospinal Fluid. Cerebrospinal fluid was 
withdrawn from the ci sterna magna immediately following 
death. It was diluted with distilled water so that 1 ml.
of this solution when mixed with one ml, of Buffer I averaged 
12 per cent of the total as determined by titration between 
pH 8 and 7® However, some experiments were conducted using 
1 ml, of undiluted cerebrospinal fluid.
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Determination of Cholinesterase Activity
Cholinesterase activity was determined using a mod­
ification of the electrometric method of Michel (36)<, The 
principle of this method consists in measuring the change 
in pH which occurs as a result of the hydrolytic action of 
cholinesterase on acetylcholine. The products of the 
reaction are choline and acetic acid. The acid formed is 
measured in a buffered solution and enzyme activity is 
expressed as pH, the change in pH in one hour. All 
determinations were made in duplicate at 25-27° c. using 
a Beckman Model G pH meter. Corrections for non-enzymatic 
hydrolysis were made using the table of corrections 
published by Michel (3Ô). The corrections for non-enzymatic 
hydrolysis given by him for erythrocytes were used for brain 
cholinesterase activity determinations. This table was 
determined for human erythrocytes and plasma and probably 
is not strictly accurate for dog brain and blood. However, 
this was a. study to compare rates of activity and the 
table is acceptable and should not affect the results 
appreciably. The table for non-enzymatic hydrolysis of 
human serum cholinesterase activity was also used for the 
determinations of dog serum cholinesterase activity.
Michel states that "The rate of pH change will be a 
satisfactory measure of enzyme activity if an approximately
17
linear relationship between these two quantities can be 
established"* This was confirmed in the present study by 
doubling the enzyme concentration which resulted in about 
a two-fold increase in velocity* The kinetics are those of 
a first order reaction during the reaction period used*
Cholinesterase activity decreases with a decrease in 
pH (4)c The pH range covered by this method is from 7®9 
to 6*0. The buffering capacity of the added enzyme source 
necessarily affects the total buffering capacity and must 
be taken into account* This has been minimized by sufficient­
ly diluting the tissues so that their buffering capacity is 
small compared to that of the buffer.
After mixing of either erythrocyte hemolysate or brain 
homogenate with the buffer, the mixture does not give a pH 
of 8.00 as Michel found with human erythrocytes* The pH of 
the mixture in these experiments was always between 7»5 and
7.9 when using erythrocytes, 7*9 and 8*05 when using brain 
and 7*69 and 7*95 when using plasma. These values are very 
near the optimal pH range of 7«50 to 8.00 for true-chclin- 
eSt erase and 8.00 to 8*50 for pseudo-cholinesterase (4)»
Since the initial pH was always very near the same value 
from sample to sample, these differences are of little or 
no significance*
(1) Buffers*
(a) Buffer I (for erythrocytes, cerebrospinal
Ig
fluid, and brain): 0«02M sodium barbital (4«1236 Gm.,);
0.004M KH2PO4 (0.5446 Gm.); O.6OM KCl (44.730 Gm.). For 
1 liter of buffer the reagents are dissolved in 900 ml. 
of water; 2g,0 ml. of o.lN HCl are added while shaking 
the solution, and the volume is then made to the mark. The 
pH of Buffer I should be g.lO at 25° C.
(b) Buffer II. (for plasma): O.OO6M sodium
barbital (1.2371 Gm.); O.OOIM KH2P0^ (0.1361 Gm.); 0.30M 
NaCl (17.535 Gm.)o For 1 liter of buffer the reagents are 
dissolved in about 900 ml. of distilled water and 11.6 ml. 
of O.lN HCl are added before diluting to volum.e. The pH of 
Buffer II should be g.OO at 25° 0.
(2) Substrate. Ampules of acetylcholine chloride 
(Merck and Co., Inc.) containing 100 mg. were used. A 
small hole was drilled into each ampule through which 
3.33 and 5.00 ml. of distilled water were added to obtain
O.I65M and O.llM solutions, respectively. A substrate 
concentration of 0.165 M was used for plasma and O.llM for 
erythrocytes, brain, and cerebrospinal fluid.
Electroshock
An I.O.Lo-Liberson Brief-Stimulus Therapy Apparatus 
Type 735 made by Offner Electronics Inc.^ was used to
Donated to the Department of Pharmacology by Dr. Coyne 
Campbell of the Coyne Campbell Sanitarium, Oklahoma City, 
Oklahoma.
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produce convulsions. Since the resistance through the head 
varies from individual to individual, this apparatus is so 
designed that the resistance is measured and thus permits 
adjustments to be made in order to administer a current 
of predetermined intensity. A pulse duration of 1 milli­
second and a frequency of 120 cycles per second were used 
in all experiments. The current and duration of treatment 
were varied and are given in the section under experimental 
results.
The animals were anesthetized with pentobarbital 
sodium (Nembutal, Abbott)^, 30 mg./Kg. I.V. The hair from 
an area on each side of the head, posterior and lateral to 
the eyes, was clipped and dovered with electrode jelly. 
Electrodes were placed over gauze squares which had been 
soaked in NaCl solution and which covered the shaved areas. 
Electrical current was then passed from bitemporal electrodes 
through the skull to produce convulsions.
Drugs
(1) Atropine dissolved in distilled water, 50 mg./ml.
(2) Metrazol ampules containing 100 mg./ml.
(3) Serpasil (Reserpine, Giba) ampules containing
2.5 mg./ml.
(4) Iletin (Insulin, Lilly) containing BO units/ml.
^ Abbott Laboratories, Veterinary Nembutal Sodium.
Each ml. contains Nembutal Sodium 60 mg., alcohol 10^ and 
propylene glycol 20%.
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(5) Di-isopropyl fluorophosphate (Bios Laboratories) 
in propylene glycol, 100 mg./mlo
CHAPTER IV 
EXPERIMENTAL RESULTS
Controls
Since each dog could not serve as its own control 
for determining brain cholinesterase activity, it was 
necessary to compute the mean value for a group of control 
dogs. Table 1 shows the results from six dogs. Deter­
minations were made on the caudate nucleus, cerebral cortex, 
erythrocytes, plasma, and cerebrospinal fluid. Cholin- 
esterase activity was either absent from the cerebrospinal 
fluid of the controls or was present in such small amounts 
that it was not detectable by this method. This was true 
even when 1 ml. of undiluted cerebrospinal fluid was used 
as the enzyme source. Thereafter, the cholinesterase 
activity of the cerebrospinal fluid from the experimental 
animals was not determined.
Nembutal
Nembutal was employed as the anesthetic in all 
experiments using electroshock. Therefore, it was 
necessary to determine if nembutal itself had any effect
21
TABLE 1
CHOLINESTERASE ACTIVITY* IN CONTROL ANIMALS
CAUDATE NUCLEUS CEREBRAL CORTEX RBC PLASMA SEX
1.04 0.98 .36 .32 M
1.04 0.84 .32 .23 M
1.07 1.70 .39 .19 M
0.87 0.92 .29 .28 M
0.86 0.89 .35 .28 M
0.90 0.82 .37 .22 F
ro 
! w
* pH/Hour
CAUDATE
TABLE 2
CHOLINESTERASE ACTIVITY* AFTER NEMBUTAL*;
CEREBRAL ERYTHROCYTES
* i^pH/Hour
* * 3 0  mg^/Kge loV.
PLASMA
NUCLEUS CORTEX , BEFORE AFTER BEFORE ^AFTER SEX
lo35' 1.10 c51 .53 .25 .28 M
1.00 0.83 .40 .41 • 17 .20 F
1.12 1.01 • 44 .40 .27 .26 M
0.87 0.79 .36 .35 • 17 .18 M
1.08 0.93 .38 .39 .15 .12 M
VO
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upon cholinesterase activity. The results of the experi­
ments obtained with a dose of 30 mg./Kg. intravenously are 
shown in Table 2. The analysis of the results using the 
standard "t" test shows that in these experiments nembutal 
had no significant effect on cholinesterase activity.
Reserpine
Plummer et al (4&) found that the most obvious effect 
of reserpine was the production of a state of quietude and 
sedation. Sixty to ninety minutes following the injection 
of 0.25 to 0.30 mg./Kg. of reserpine intravenously, they 
found that a dog usually developed this quiescent state 
although miosis appeared much sooner. They also observed 
an augmentation of motor activity in the gastrointestinal 
tract. In the present study, a dosage of 0.4 mg./Kg. of 
reserpine^ was injected intravenously and after two hours 
the animals were sacrificed. This dosage regularly produced 
miosis and defecation. The results of these experiments 
are shown in Table 3» It is evident that reserpine had no 
significant effect on erythrocyte or plasma cholinesterase 
activity. Analysis of the difference between the mean 
value of brain cholinesterase activity of these animals and 
of the control animals shows that there is no significant 
change in cholinesterase activity following reserpine.
^Supplied by'Ciba Pharmaceutical Products, Inc.
CAUDATE
TABLE 3
CHOLINESTERASE ACTIVITY* AFTER RESERPINE**
ERYTHROCYTE PLASMA
NUCLEUS BEFORE. ■ after BEFORE- AFTER SEX
1.09 o 36 .38 .24 .23 M
loll o34 .37 .22 o21 M
0.92 .38 .37 .27 .23 M
1004 o37 .39 .20 .20 M
1006 0 41 .38 .15 .16 M
* pH/Hour
** Oo4 mgo/Kgo IoV<
rovn
CAUDATE
TABLE 4
CHOLINESTERASE ACTIVITY* AFTER ELECTROSHOCK**
CEREBRAL ERYTHROCYTE PLASMA hematocrit $
pH/Hour
** So milliamperes for lo3 seconds
NUCLEUS CORTEX BEFORE - after BEFORE. AFTER SEX BEFORE AFTER
loOS 0.90 .30 .29 .09 .11 F —
1.24 0.92 .28 .28 .23 .24 M 43 42
1.22 0.86 .44 .40 .40 .21 F 40 40
10 04 0.80 .32 .36 014 .14 M 37 36
I0O6 0.89 .34 .35 .24 .27 M 40 40
! M 
I o\
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Electroshock 
The animals in this group were anesthetized with 
Nembutal, 30 mg./Kg. intravenously. Table 4 summarizes 
the results obtained by passing a current of Ô0 milliamperes 
for 1.3 seconds (104 milliampere-seconds) through the intact 
skull from bitemporal electrodes. This is comparable to the 
range in milliampere-seconds used clinically in humans. 
Hemoconcentration is known to occur in patients following 
electroshock, which should increase the plasma cholinesterase 
activity. The dosage used in these experiments did not 
alter the hematocrit values and an analysis of the data 
shows that there was no significant change in cholinesterase 
activity of brain or blood.
Atropine. Metrazol and Insulin 
Table 5 shows the results obtained with atropine, 
metrazol, and insulin. These experiments were conducted 
using the brain supernatant liquid and consequently little 
information is to be obtained from the measurements of brain 
cholinesterase activity. However, the data shows that none 
of the drugs in this group had a significant effect upon 
either erythrocyte or plasma cholinesterase activity.
At the dosage levels indicated, convulsions were produced 
by each of these drugs.
TABLE 5
CHOLINESTERASE ACTIVITY* AFTER ATROPINE, METRAZOL, AND INSULIN
DRUG DOSE BRAIN** BEFORE. .a f t e r BEFORE AFTER SEX
Atropine 20 mgo/Kgo loVo .45 .38 .34 o20 o21 M
Atropine 60 mgo/Kgo loVo oSO .39 .26 .27 M
Metrazol 20 mgo/Kgo leVo o66 .30 .29 = 17 .19 M
Metrazol 20 mgo/Kgo loVo .63 .46 .43 .30 .31 M
Metrazol 20 mgo/Kgo loVo, = 73 .46 = 46 0I6 0I4 M
Insulin 400 units loVo oS2 .34 .37 .23 .22 M
Insulin 200 units I.Vo oÔO .38 «44 .22 .23 M
* pH/Hanr
** The mean cholinesterase activity of 15 control dogs when using brain 
supernatant liquid was Oo7#
ro
00-
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DFP and DFP Followed by Electroshock 
Table 6 summarizes the results obtained following 
DFP, 2 mgo/Kgo loVo, and Table 7 the results of the same 
dose of DFP followed by electroshocko Nembutal, 30 mgo/Kgo
I.Vo, was given to the animals prior to electroshocko In 
these experiments using electroshock, the dosage was Ô0 
milliamperes for 5 seconds and this was repeated 5 times 
within 5 minuteso This dosage regularly produced violent 
convulsions accompanied by urination, defecation, and 
profuse salivationo Hemoconcentration occurred in 4 of 6 
experiments; however, there was no change in either the 
plasma or the erythrocyte cholinesterase activity. Analysis 
of the difference between the mean brain cholinesterase 
activity of these animals and the mean brain cholinesterase 
activity of those animals receiving only DFP shows there 
is no difference between the two groups.
Since no change in cholinesterase activity was observed 
following nembutal, reserpine, and electroshock with nembutal, 
the brain cholinesterase activity determinations of all these 
dogs were grouped together to serve as controls. This gives 
a total of 21 dogs whose mean brain cholinesterase activity 
is 1,0$ tt^,03 pH units. The standard deviation is 0,12 and 
the median value is 1,06« Blood cholinesterase determina­
tions were made on 61 dogs. The control erythrocyte mean
TABLE 6
CHOLINESTERASE ACTIVITY* AFTER DFP**
CAUDATE
NUCLEUS
ERYTHROCYTE 
BEFORE. . AFTER
PLASMA
BEFORE AFTER SEX
.59 .55 .20 .22 .03 F
.31 .44 .22 . 14 .02 F
.39 .40 .19 .21 .01 M
.51 .47 .31 .20 .02 F
.32 .50 .21 .26 .03 F
VO
O
^ pH/Hour
** 2 mgo/Kg. loV,
TABLE 7
CHOLINESTERASE ACTIVITY* AFTER DFP** FOLLOWED BY ELECTROSHOCK***
CAUDATE
NUCLEUS
ERYTHROCYTE 
BEFORE, AFTER
PLASMA 
BEFORE- AFTER SEX
HEMATOCRIT % 
BEFORE AFTER
^26 .55 .16 o20 .03 M 45 56
o21 .27 olO .37 .02 M 54 54
.52 .35 o20 .23 .05 M 40 40
o43 .24 oil .15 .06 M 40 51
.51 o 56 .34 o2S o04 F 42 49
.51 o30 .19 .19 .03 M 49 60
* ^  pH/Hour 
* *  2 m g o / K g o  l o V o
*** Ô0 milliamperes for 5 seconds and repeated 5 times within 5 minutes
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was 0.41:t»02 pH units with a median value of 0»39o The 
control plasma mean was Oo23dioOO pH units with a median value 
of 0»23o The difference between the mean and the median was 
not statistically significant; one-third of all the obser­
vations wereJrl standard deviation outside the mean; and 
1.2$ times the average deviation closely approximated the 
computed standard deviation of brain, erythrocyte, and 
plasma cholinesterase activity. This shows that the enzyme 
in each of the three tissues studied follows a normal 
distribution curve. Therefore, the mean value for brain 
cholinesterase activity which was computed from 21 obser­
vations can be used as the control value for each exper­
imental animal with a reasonable degree of accuracy.
Figure 1 shows brain cholinesterase activity plotted 
against the erythrocyte cholinesterase activity for the 
control group. There is a considerable spread of the 
points around the line, and the coefficient of correlation 
(0.4^6) indicates that there is only a fair degree of 
correlation between the two variables.
Table Ô presents the data obtained from 20 of the 21 
control dogs in another manner. It shows the quotients of 
brain cholinesterase activity/erythrocyte cholinesterase 
activity. The 2nd observation in Table 4 was not included 
in this series since the quotient is much larger than the 
others. The mean value obtained was 2.82 and the standard
33
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TABLE 8
RELATIONSHIP BETWEEN BRAIN AND ERYTHROCYTE 
CHOLINESTERASE ACTIVITY* OF THE CONTROLS
QUOTIENT
CAUDATE NUCLEUS RBC CAUDATE NUCLEUS RBC
1.04 .36 2.88
1.04 .32 3.25
1.07 .39 2.74
0.87 «29 3.00
0.86 .35 2
0.90 .37 2.43
1.35 .53 2.54
1.00 .40 2.50
1.12 .44 2.54
0.87 .36 2.41
1.08 .38 2.84
1.08 .30 3.60
1.22 .44 2.77
1.04 .32 3.25
1.06 .34 3.11
1.09 .36 3.02
loll .34 3.26
0.92 .38 2.42
1.04 .37 2.81
1.06 .41 2.58
* A. p7/Hour
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deviation was Oo34o The mean deviation of all the obser­
vations from 2oê2 is only 0.28 or 10%. This demonstrates 
a better correlation between the brain cholinesterase 
activity and the erythrocyte cholinesterase activity of the 
control group than when the data is plotted graphically.
A good correlation would be expected to exist between these 
two variables prior to administration of DFP if one was to 
exist following its administration.
DFP, 2 mg./Kg., was injected intravenously. A con­
centrated solution containing 100 mg./ml. was used so that 
the total volume injected ranged from about .18 to .35 ml. 
This dosage produced no overt signs of toxicity. After 
thirty minutes, a blood sample was taken and the animal 
sacrificed. Nachmansohn and Feld (42) reported that DFP 
which has not reacted with the enzyme, is retained in brain 
tissue. They showed this by determining the brain cholin­
esterase activity of a control animal and the brain 
cholinesterase activity of an experimental animal and then 
homogenizing together a piece of brain tissue from each 
animal. The observed difference averaged 33 per cent 
greater inhibition than the calculated difference. If this 
is true, it would appear to explain why a better correlation 
of blood to brain enzyme activity following inhibition by 
DFP has not been established. However, in the present study, 
this could not be confirmed by experimentation and it appears
36
that in the dosage employed, there is no DFP remaining in 
or upon the nerve cell membrane to react with free enzyme 
in the homogenate. Freedman and Himwich (19) found no 
evidence of retained DFP when using the whole rat brain 
following a dose of 2 mgo/Kgo subcutaneously»
It can be seen from Tables 6 and 7 that plasma 
cholinesterase is most sensitive to inhibition by DFP, 
followed by brain and then erythrocyte cholinesterase. It has 
been shown by other investigators (25,44) that symptoms of 
toxicity are not manifested until the brain cholinesterase 
activity has been depressed to about 10-20^ of control 
levels. In 11 of 12 experiments, the brain enzyme is 
inhibited to a greater extent than the erythrocyte enzyme. 
Figure 2 shows the relationship between brain and erythro­
cyte cholinesterase activity as the per cent of control 
activity remaining following DFP. Included in this group 
are those which were given DFP followed by electroshock.
It can be seen that the level of activity of brain and 
erythrocyte cholinesterase approach zero simultaneously. 
Extrapolation of the computed line to intersect the axis 
which represents erythrocyte cholinesterase activity indicates 
that when the brain enzyme activity is at zero, the erythro­
cyte activity might still be about 2 to 3 per cent of control 
levels.
Figure 2 shows graphically that there is a good re-
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Tationsnip between brain and erythrocyte cholinesterase 
activity following the administration of DFP» The line in 
this figure was fitted by the method of least squares. It 
shows a good degree of linearity between the two variables 
and by analysis it is found to be significant to the «01 
level. The computed coefficient of correlation for these 
12 observations is 087® It will be noted that this is 
considerably better than that found for the control group. 
Figures 3 and 4 show the results when the data from 
Tables 6 and 7 are plotted separately. Further analysis 
shows that the coefficient of correlation of brain cholin­
esterase activity to erythrocyte cholinesterase activity 
for Table 6 is ,860, and when the line for Figure 3 is 
fitted by the method of least squares, it is significant to 
the ,02 level. Fitting the line in Figure 4 and analyzing 
for its significance shows it to be significant to the ,01 
level. The computed coefficient of correlation for Table 
7 is very high at ,960,
Plasma cholinesterase activity appears to have no 
correlation to erythrocyte or brain cholinesterase activity, 
either in the control or experimental group.
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CHAPTER V 
DISCUSSION
Data obtained from measurements of the cholinesterase 
activity of tissues (caudate nucleus, cerebral cortex, 
erythrocytes, plasma and cerebrospinal fluid) of the dog 
have been presented» This was a study requiring statistical 
methods of analysis. Two approaches utilizing statistical 
methods were taken in the analysis: (1) The significance
of the difference between the means of the control and the 
experimental group and (2) A mathematical derivation of the 
correlation between two biological variables»
As long as it is recalled that quantitative biological 
measurements include inherent variations; that a statistical 
analysis is primarily a function of probability; and that the 
experimental data must be of such a nature that the applica­
tion of statistics is reasonable, then over-emphasis of the 
results obtained by such procedures is less likely to occur. 
The data presented show that there is no effect of 
nembutal on cholinesterase activity of blood and brain. It 
is known that an accumulation of bound-acetylcholine occurs 
following nembutal. This probably is the result of decreased 
central activity (6). Several investigators have used the
41
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supernatant liquid of homogenized brain tissue to determine 
the effect of drugs upon cholinesterase activity "in vivo". 
Using these methods, barbiturates have been reported to 
decrease cholinesterase activity approximately 5 per cent 
in chronic experiments (57,50). Nachmansohn and Feld (42) 
have shown that the major part of brain cholinesterase 
activity resides in the sediment. This was confirmed in 
the present study. Therefore, results obtained using the 
supernatant liquid are probably not accurate, especially 
when changes of small magnitude are observed.
The evidence for interference with the acetylcholine- 
cholinesteraso system in certain mental disorders has been 
given. Convulsive therapy, utilizing either insulin, metrazol 
or electroshock is used in some types of mental illness.
On the basis of Sherwood*s results (56), an increase in 
cholinesterase activity following convulsive therapy might 
be expected. However, there are other possibilities which 
might bring about a temporary reduction of enzymatic activity- 
following electroshock; (1) It is known that an increased 
hydrogen ion concentration will lower cholinesterase activity. 
Consciousness and other high levels of central nervous system 
activity depend upon the normal function of central synapses. 
Minute pathological changes occurring in the enzyme-substrate 
system at localized sites might be transientaly corrected by 
an increased concentration of hydrogen ions as a result of
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electroshocko Since the structure of acetylcholine does not 
change with a change in pH, Wilson (66) believes changes 
in the rate of its hydrolysis may involve alterations in the 
protein structure of the enzyme* He postulated the following 
explanation for the change in cholinesterase activity with 
a change in pH,
H"^  OH- 
EHglzrj E H ^ E ” 4- HgO
where EH, the active enzyme, is arbitrarily assigned a 
relative charge of zero. The forms EH2 and E~ either 
cannot form complexes at all or they are not active. (2)The 
other possibility whereby electroshock might produce 
cholinesterase inhibition consists of enzymatic inhibition 
as a result of the substrate concentration in excess of the 
optimum. The bound-acetylcholine content of the brain is 
reduced following electrical stimulation (52). Although it 
is unlikely that large quantities of acetylcholine are 
released into the circulation following electrical stimulation, 
it is known that cholinesterase is located exclusively at 
the neuronal surface where bioelectrical phenomena are said 
to occur. A sudden release of large quantities of acetyl­
choline could, therefore, conceivably produce inhibition of 
the enzyme, because "in vitro" studies have shown that 
true-cholinesterase activity is inhibited by substrate 
concentrations which are greater than the optimum. It is
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thought that the active surface of the enzyme possesses a 
negative and a positive combining site* The quaternary 
nitrogen atom in the acetylcholine molecule is electro­
positive while the esteratic site has been shown to possess 
electro-negative properties* Therefore, the enzyme is 
believed to interact with the substrate at two sites to 
form an active enzyme-substrate complex. It has been shown 
that one molecule of acetylcholine probably reacts with one 
molecule of enzyme. Haldane (22) has postulated that two 
molecules of substrate may react with one molecule of enzyme 
and thereby form an inactive complex, resulting in enzyme 
inhibition. However, it appears from the results obtained 
in this study, that no change in cholinesterase activity 
occurred following insulin, metrazol, atropine, or electro­
shock.
The clinical and experimental evidence presented by 
Sherwood (55,56) suggested the possibility of decreased 
cholinesterase activity or of acetylcholine accumulation 
in schizophrenia. Therefore, it was decided to simulate 
this condition by reducing brain cholinesterase activity by 
about 50 per cent with DFP and then applying electroshock.
It is generally believed that the release of bound, inactive 
acetylcholine to the free, active form occurs as a result 
of the nerve impulse. Experimental evidence indicates that 
either all or nearly all of the bound acetylcholine is 
released when the nerve stimulus is of threshold intensity.
4-5
The present experiment suggests several mechanisms whereby 
acetylcholine would be expected to accumulate in brain tissue 
for release by electroshock. Following DFP, the concentration 
of acetylcholine is approximately 102 per cent greater than 
before DFP (37)« An increase in bound-acetylcholine was 
found to occur in brain under nembutal anesthesia (6). 
Experimental evidence indicated an increase synthesis of 
bound acetylcholine when free acetylcholine was added to the 
"in vitro" system (36). Furthermore, Augustinsson has 
pointed out that the optimal substrate concentration changes 
as the protein cholinesterase molecule changes in polarity.
As the molecule increases in negativity, the optimal activity- 
substrate concentration decreases. Since cholinesterase is 
located at the neuronal surface, he believes that when 
depolarization occurs, the neuronal surface become negative 
and enzyme activity will be optimal at lower acetylcholine 
concentrations. In spite of these factors, no significant 
change in cholinesterase activity was found following 
electroshock. The hydrolysis of acetylcholine by cholin- 
esterase occurs at an extremely high rate of speed. One 
molecule of enzyme may split one molecule of acetylcholine in 
about 3 or 4 microseconds (43). Nachmansohn states that,
"No other chemical reaction known to be connected with nerve 
activity has a comparable speed”. This may be a decisive 
factor in the failure of these experiments to detect a
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change in cholinesterase activity following DFP plus electro­
shock.
Reserpine has the following pharmacological properties: 
It has been reported to increase intestinal motility, to 
produce miosis, and bradycardia (46). Following excision 
of the ciliary ganglion, miosis does not occur which shows 
that pupillary constriction is not produced peripherally {5)« 
Reserpine does not increase the movements of the isolated 
intestine (65,5). The site of action is thou^t to be in 
the hypothalamus (4Ô). It is possible that reserpine could 
either selectively inhibit cholinesterase in the hypothalmus 
or could produce selective inhibition on the basis of a 
differential enzyme concentration in this region. In this 
event, the selection of tissue other than the hypothalamus 
probably would not show enzyme inhibition. It is unlikely 
that the above two conditions would exist without associated 
inhibition in the caudate nucleus. Sometimes only a slight 
change may result in a considerable functional difference.
An example is the diuresis resulting from about one per cent 
change in reabsorption of water from the renal tubules. 
However, as previously mentioned, brain cholinesterase 
must be inhibited to a considerable extent before marked 
funtional changes occur. Nachmansohn has shown by "in vitro" 
studies that an increased concentration of DFP is required 
to produce a comparable inhibition as the dilution of
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cholinesterase is increased® This would indicate that areas 
containing a lesser concentration of cholinesterase would 
require a higher concentration of DFP than would be required 
for an area of greater cholinesterase concentration in order 
to produce equal inhibition® Therefore, those areas 
possessing more cholinesterase should show enzyme inhibition 
earlier than those areas possessing less enzyme.
The data presented show that a relationship exists 
between brain and erythrocyte cholinesterase activity 
following DFP. Koelle and Gilman (25) showed the sensitivity 
of dog cholinesterase to inhibition by DFP when tested 
"in vitro". The sensitivity was in the increasing order 
of brain, erythrocyte, and serum cholinesterase. However, 
their chronic study using 4 dogs (26) shows the brain 
enzyme to be inhibited to the greatest extent at the end of 
24 weeks following an initial injection of DFP. This was 
explained by the fact that since DFP produces irreversible 
inhibition, new enzyme must be formed in order to show a 
return of activity. It appears that the plasma and erythro­
cyte enzyme are formed at a faster rate than that of brain. 
This is a reasonable explanation and such has been shown to 
occur in rats (20,25). It is also known that DFP has a high 
lipid solubility and for this reason might be expected to 
inhibit brain cholinesterase to a greater extent than 
erythrocyte cholinesterase if measurements are made soon 
after a single dose. In the present study, brain cholin-
kô
esterase was in fact inhibited to a greater extent than 
that of erythrocyte, and the solubility of DFP in lipids 
may be the reason why this data is in disagreement with the 
sensitivities reported by Koelle and Gilman.
According to the experiments of various investigators, 
it appears that the species, dosage, and time of measurement 
of enzyme activity following DFP all affect the correlation 
of brain to blood enzyme activity. For instance, "in vitro" 
studies have shown that rabbit, rat and human brain cholin­
esterase are more sensitive to inhibition by DFP than is 
their erythrocyte enzyme (25,33)« The reverse is true in 
the dog (25)« Freedman, Willis and Himwich (20) have shown 
that following the administration of DFP, 1 mg./Kg. subcu- 
taneously, the rat brain cholinesterase activity is depressed 
to a greater extent than that of erythrocytes. This extends 
from a period immediately following it s administration 
throughout the remaining ten day experimental period. In 
another experiment, they found that following a larger dose,
2 mg./Kg., the erythrocyte enzyme was depressed more than 
that of the brain for about 4 days, after which time they 
believe erythrocyte cholinesterase regeneration rates 
overtook those of the brain, and consequently the brain 
enzyme was inhibited to a greater extent.
It is generally agreed that the symptoms following 
toxic doses of DFP are the result of an accumulation of 
acetylcholine which in turn results from cholinesterase
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inhibition. Holmstedt (23) has shown the relationship 
between toxicity and cholinesterase inhibition. He plotted 
the logarithm of the L.D.^g dose of the inhibitor against 
the logarithm of the concentration producing 50 per cent 
inhibition. A straight line resulted. Freedman, Willis 
and Himwich (20) have done about the same thing in another 
way. They correlated signs of toxicity which cholinesterase 
inhibition and found a significant correlation.
Some evidence indicates that DFP produces symptoms 
of toxicity that cannot be accounted for by cholinesterase 
inhibition; however, to date no mechanisms have been proposed.
CHAPTER VI 
CONCLUSIONS
1. The effect of physical and chemical agents upon 
cholinesterase activity was studied in the brain (caudate 
nucleus and cerebral cortex), plasma, erythrocytes, and 
cerebrospinal fluid.
2. The method of Michel was modified to measure 
cholinesterase activity of the above tissues of the dog.
3. The whole tissue homogenate of the brain was 
found to be necessary to determine quantitatively the effect 
of drugs upon cholinesterase activity "in vivo".
4. Nembutal was found to have no significant effect 
upon cholinesterase activity.
5. Dogs appeared to show no overt signs of toxicity 
when brain cholinesterase activity was depressed to within 
30 to 50 per cent of control levels, and when erythrocyte 
cholinesterase activity was depressed to within 30 to 60 
per cent of control levels.
6. Cerebrospinal fluid was found to contain no 
detectable cholinesterase activity.
7. It was found that erythrocyte cholinesterase
activity measurements afford a relatively accurate means of
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estimating brain cholinesterase activity when measurements 
are made soon after a single dose of DFP,
So Contrary to expectations, depression of brain 
cholinesterase activity to within about 50 per cent of 
normal levels by DFP followed by electroshock produced no 
significant change in cholinesterase activity*
9. Metrazol, insulin, and atropine were found to have 
no effect upon cholinesterase activity of blood althou^ 
copvulsions were produced.
10o No retained di-isopropyl fluorophosphate (DFP) 
was found in brain tissue following a dose of 2 mg./Kg. I.V.
11. The sensitivity to inhibition by DFP "in vivo" 
was in the increasing order of erythrocytes, brain, and 
plasma cholinesterase activity.
CHAPTER VII 
SUMMARY
Cholinesterase activity is inhibited by di-isopropyl 
fluorophosphate (DFP) and a correlation was found to exist 
between erythrocyte and brain cholinesterase activity»
A better relationship appears to exist following DFP plus 
electroshock than with DFP alone» There was no significant 
change in cholinesterase activity following nembutal, 
reserpine, insulin, metrazol, atropine or electroshock. The 
cerebrospinal fluid either contains no cholinesterase or it 
was present in such small quantities that it was not detected 
by this method. Plasma cholinesterase activity appears to 
bear no relationship to erythrocyte or brain cholinesterase 
activity, either before or after the drugs used. Following 
an acute exposure to DFP, brain cholinesterase activity was 
inhibited to a greater degree than was erythrocyte cholin­
esterase.
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